tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Bluejay Diagnostics Amends Agreement with Toray Industries

Story Highlights
Bluejay Diagnostics Amends Agreement with Toray Industries

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Bluejay Diagnostics ( (BJDX) ).

On July 23, 2025, Bluejay Diagnostics announced an amendment to its agreements with Toray Industries, extending the deadline to establish an alternative manufacturing site for Symphony cartridges to October 23, 2026. The amendment also confirms that Toray has fulfilled its know-how obligations and requires Bluejay to pay $71,212 for a final supply of chip components before the supply agreement expires on October 23, 2025.

Spark’s Take on BJDX Stock

According to Spark, TipRanks’ AI Analyst, BJDX is a Underperform.

Bluejay Diagnostics’ stock is heavily impacted by its poor financial performance, with no revenue and continuous losses. The technical indicators suggest a bearish trend, and valuation is challenging due to the negative P/E ratio. Improvements in equity are noted but overshadowed by the lack of profitability and revenue generation.

To see Spark’s full report on BJDX stock, click here.

More about Bluejay Diagnostics

Bluejay Diagnostics, Inc. operates in the medical diagnostics industry, focusing on developing and supplying diagnostic solutions, including the Symphony cartridges.

Average Trading Volume: 804,551

Technical Sentiment Signal: Sell

Current Market Cap: $2.33M

See more insights into BJDX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1